Interstitial Lung Disease
Risk score predicts interstitial lung disease risk at first systemic sclerosis diagnosis
PHILADELPHIA — A novel risk score accurately predicted interstitial lung disease in patients with systemic sclerosis at the time of diagnosis, which may reduce unnecessary CT screening, according to data presented at ACR Convergence 2022.
Air pollution raises mortality risk, worsens lung function in fibrotic ILD
In patients with fibrotic interstitial lung disease, exposure to small particulate matter was linked to increased mortality, poor lung function and faster disease progression, according to a study in JAMA Internal Medicine.
‘Time lost is lung lost’: Early diagnosis critical in pulmonary fibrosis
NASHVILLE, Tenn. — Delayed diagnosis of pulmonary fibrosis is an unfortunate reality for many patients, but experts are seeking to address this problem by closing knowledge gaps and increasing awareness of the disease.
Collaboration with pulmonology key to managing ILD in autoimmune disease
SAN DIEGO — A clear intervention plan and collaboration with pulmonology are key to managing patients with interstitial lung disease in autoimmune conditions, according to a speaker at the Congress of Clinical Rheumatology West.
Future of systemic sclerosis treatment will likely be combination therapy
SAN DIEGO — Patients with systemic sclerosis will likely require multidisciplinary management with combination therapy to treat the myriad complications that may arise, according to a speaker at the Congress of Clinical Rheumatology West.
Cyclophosphamide treatment for systemic sclerosis linked to lower ovarian reserve in women
NASHVILLE, Tenn. — In women with systemic sclerosis, cyclophosphamide therapy negatively correlated with ovarian reserve, according to a presenter at the CHEST Annual Meeting.
Nintedanib maintains safety, efficacy long-term in patients with SSc-associated ILD
Nintedanib maintains its safety and efficacy for up to 3 years in patients with systemic sclerosis-associated interstitial lung disease, according to data published the Annals of the Rheumatic Diseases.
Patients with ILD living in rural areas do not have worse outcomes, study finds
NASHVILLE, Tenn. — People with interstitial lung disease living in rural areas do not appear to have greater risk for death, lung transplant, acute exacerbation or disease progression compared with those in urban areas, researchers reported.
Influenza vaccination shows mixed results on all-cause mortality in patients with ILD
Among patients with interstitial lung disease, those who received an influenza vaccination demonstrated a significant reduction in all-cause mortality in two of the four seasons evaluated in a recent study.
Higher-dose treprostinil yields greater improvements in pulmonary hypertension-ILD
Patients with pulmonary hypertension associated with interstitial lung disease had better outcomes with a higher dose of inhaled treprostinil, as compared with a lower dose or placebo, according to a study.